Gastrointestinal Neuroendocrine Tumor
📧 Sign up to get email alerts when something new happens for Gastrointestinal Neuroendocrine Tumor.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-08-25Clinical Trial Results: Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors [Phase 2]
Phase 2 trial results for nab-sirolimus in patients with well-differentiated neuroendocrine tumors (NETs) of the gastrointestinal tract, lun…
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Multicenter Trial of ESK981 in Patients With Select Solid Tumors [Phase 2]
This document reports a Phase 2 multicenter clinical trial of ESK981 in select solid tumors. The study is currently recruiting across specif…
-
CLINICAL_TRIALS trial_result · 2026-03-19Clinical Trial Update: Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients [Phase 1]
Phase 1 trial of Cabotamig (ARB202) in advanced gastrointestinal cancers has completed; no specific efficacy results are provided in the doc…
-
CLINICAL_TRIALS research · 2026-03-10Clinical Trial Update: Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy [Phase 1, Phase 2]
Recruitment is ongoing for a Phase 1/2 study of the radiopharmaceutical [212Pb]VMT-alpha-NET targeting somatostatin receptors in metastatic …
-
CLINICAL_TRIALS research · 2025-11-25Clinical Trial Update: [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers [Phase 1]
Phase 1 trial evaluating the radiopharmaceutical [212Pb]VMT-Alpha-NET across multiple somatostatin receptor–positive cancers, with recruitme…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-07-02Clinical Trial Update: Non-Invasive Artificial Intelligence-Based Platform MonIToring Program (NIP IT!)
A recruiting clinical study from University Health Network evaluating a non-invasive AI-based platform for patient monitoring, named NIP IT!…
-
CLINICAL_TRIALS research · 2024-08-26Clinical Trial Update: EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers [Phase 1, Phase 2]
EMB-01 is being studied in a Phase 1/2 trial for advanced or metastatic gastrointestinal cancers and is currently recruiting. The sponsor is…
-
CLINICAL_TRIALS research · 2024-07-16Clinical Trial Update: Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors [Phase 2]
A Phase 2 clinical trial is evaluating nab-sirolimus in patients with well-differentiated neuroendocrine tumors of the gastrointestinal trac…
-
CLINICAL_TRIALS trial_result · 2019-05-24Clinical Trial Update: Etoposide/Cisplatin Compared With Irinotecan/Cisplatin for Advanced Gastrointestinal Neuroendocrine Tumor G3 Type [Phase 2]
Phase 2 trial comparing etoposide/cisplatin to irinotecan/cisplatin for advanced gastrointestinal neuroendocrine tumors/g3.
-
FDA approval · 2018-03-09FDA Approved: OCTREOTIDE — Supplemental Application (Fresenius Kabi USA, LLC)
FDA approved a supplemental application for octreotide acetate from Fresenius Kabi USA, LLC.
-
CLINICAL_TRIALS trial_result · 2017-10-19Clinical Trial Update: A Ph 2 Study of Fosbretabulin in Subjects w Pancreatic or Gastrointestinal Neuroendocrine Tumors w Elevated Biomarkers [Phase 2]
Phase 2 study of Fosbretabulin in pancreatic or gastrointestinal neuroendocrine tumors has completed with results posted.
-
CLINICAL_TRIALS research · 2017-05-31Clinical Trial Update: Everolimus TDM to Predict Long Term Toxicity
A clinical trial evaluates whether therapeutic drug monitoring of everolimus can predict long-term toxicity in cancer patients.
-
CLINICAL_TRIALS withdrawal · 2016-04-05Clinical Trial Update: Randomized Phase III of PRRT Versus Interferon [Phase 3]
A Phase III randomized trial comparing peptide receptor radionuclide therapy (PRRT) to Interferon for gastrointestinal neuroendocrine tumors…
-
CLINICAL_TRIALS trial_result · 2009-10-07Clinical Trial Update: High Dose Somatostatin Analogues in Neuroendocrine Tumors [Phase 2]
A Phase 2 trial evaluating high-dose somatostatin analogues in neuroendocrine tumors has completed.